PRINCETON, N.J., June 28, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced today that its bioanalytical laboratory in Quebec City, Canada, has received formal recognition from the Standards Council of Canada (SCC) for its compliance with the Organization for Economic Co-operation and Development (OECD) Principles of Good Laboratory Practice (GLP).
"After an in-depth review by a four-person inspection team, the Standards Council of Canada awarded us with official recognition of GLP compliance, acknowledging the premier level of quality and compliance maintained in our laboratory," said Tony Jones, Executive Director, Quality Assurance and Compliance.
Mr. Jones continued, "We have a long track record of successful inspections from global regulatory bodies, including a re-certification from Brazil's ANVISA just prior to the SCC inspection. This OECD GLP recognition consolidates our position as the partner of choice for companies seeking assured international registration of their products."
The final guidance describing the program was announced by Health Canada in April 2010. Thirty-four countries in North America, Europe and Asia constitute the OECD, an inter-governmental organization that pursues, among many other policies, the international harmonization of test methods and good laboratory practices. Upholding the principles of GLP ensures that a laboratory's quality system and management controls are consistent and reliable, which is essential for producing high quality and valid test data.
PharmaNet's laboratories offer complete bioanalytical services for small and large molecules across the continuum of drug development. The company's other laboratory in Princeton, NJ, is also GLP-compliant. Together the labs offer an extensive method development and validation services, with more than 1000 validated assays and rapid sample handling capabilities.
PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.
Contact: Anne-Marie Hess
Phone: (609) 951-6842
SOURCE PharmaNet Development Group, Inc.